AstraZeneca pediatric NEXIUM trial for erosive esophagitis listed as completed
A Phase 3 AstraZeneca trial testing NEXIUM maintenance dosing in children with erosive esophagitis has reached completed status on ClinicalTrials.gov.
AstraZeneca's pediatric gastroenterology program shows one update this week.
- NCT05267613, a Phase 3 trial of NEXIUM (esomeprazole) for maintenance of healing of erosive esophagitis in patients aged 1 to 11 years1, is listed as completed with a primary completion date of 2026-08-10. The trial enrolled 53 participants1 and compared a high dose (Nexium 20mg) against a low dose (Nexium 10mg)1 as active comparator arms. The primary outcome was presence or absence of erosive esophagitis at Week 24, assessed by esophagogastroduodenoscopy at the end of the 16-week maintenance phase.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.